Stockreport

Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation [Seeking Alpha]

Inovio Pharmaceuticals, Inc.  (INO) 
NASDAQ:AMEX Investor Relations: ir.inovio.com/investors/default.aspx
PDF The company's flagship drug, INO-3107, shows promise for treating recurrent respiratory papillomatosis and VGX-3100 for HPV-related cervical and anal high-grade squamou [Read more]